Clinical Trials · NCT04109547
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 521
- Start date
- Oct 2019
- Locations
- 66 sites, 6 countries
- Primary endpoint
- Change From Baseline in Glycosylated Haemoglobin (HbA1c)